UDC 618.11-007.1

Polycystic ovary syndrome (PCOS), an endocrine and metabolic disorder in women of reproductive age, is characterized by high androgen levels, irregular periods, and small cysts in the ovaries. PCOS affects approximately 10 % of reproductive age women of all races and ethnicities. PCOS has been recognized to affect women of reproductive age since antiquity and in the 21st century, it emerges as the most widespread and serious reproductive metabolic disorder in the world. PCOS is a multifactorial disorder that affects both the reproductive and metabolic health of women. In addition, PCOS is a leading symptom of infertility in women. Nevertheless, women with PCOS who become pregnant unfortunately have an increased risk of complications, such as gestational diabetes mellitus (GDM), preterm birth. Many people believe GDM disappears after childbirth, despite the fact that GDM is a warning symptom of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. According to growing evidence, GDM complicates 40 % of PCOS pregnancies, suggesting that PCOS is a risk factor for GDM. Hence, PCOS is a lifelong disorder that can eventually lead to various long-term health complications, including chronic menstrual irregularity, infertility, endometrial hyperplasia, and endometrial cancer. Thus, it’s a scientific fact that both PCOS and GDM are significantly associated with each other. However, most studies on the risk of GDM in PCOS patients are retrospective. Therefore, there is no strong evidence whether PCOS is a risk factor for GDM or any other related factor. PCOS, a polygenic endocrinopathy, is in a true sense a set of diseases that worsen the state of the body. Reproductive and metabolic disorders associated with PCOS cause several clinical symptoms, such as irregular and painful periods, hirsutism, acanthosis nigricans, acne, psoriasis, anxiety, mood swings, patterned baldness, cardiovascular problems, type 2 diabetes, infertility, pelvic pain, low libido, low self-esteem, etc. Further studies are needed to understand the genetic and epigenetic contributions of PCOS, PCOS-related comorbidities, the role of placenta in nutrient availability, and influence of medications that may affect the long-term offspring health.

UDC: 618.19-009.7-085

More than 82 % of women of reproductive age note pain in the mammary gland. Every fifth woman feels severe pain (mastalgia) and swelling (mastodynia) in the mammary gland. Cyclic mastalgia is combined with hyperprolactinemia. Hyperprolactinemia occurs when dopamine does not suppress pituitary function enough to reduce prolactin release. Agni casti fructus, known for its dopaminergic activity, relieves pain and discomfort in the mammary glands. 50 patients were under observation. Only 10 % of patients felt mild pain, 32 % experienced moderate pain, 50 % assessed it as severe, and 8 % experienced extreme pain. After the treatment, the complete absence of pain was noted by 76 % of patients. The results of the conducted studies indicate a high efficiency of 76 % and the safety of using Agni casti fructus in treating mastalgia and mastodynia. The high efficiency in the treatment of mastalgia and mastodynia with the herbal medicine Agni casti fructus without the additional use of hormonal drugs can be explained by the fact that this drug normalizes the hormonal balance of a woman